876-32-4

Usage

Uses

Used in Pharmaceutical Industry:
4-Methoxy-N-methylbenzylamine hydrochloride is used as a pharmaceutical intermediate for the synthesis of various drugs, including antidepressants and antihypertensive medications. Its role in the development of these medications is crucial, as it serves as a building block in the creation of active pharmaceutical ingredients.
Used in Organic Chemistry:
In the realm of organic chemistry, 4-Methoxy-N-methylbenzylamine hydrochloride is utilized as a building block for the preparation of other important chemical compounds. Its versatility in chemical reactions and its ability to form new compounds make it a valuable component in the synthesis of a wide range of products.

InChI:InChI=1/C9H13NO.ClH/c1-10-7-8-3-5-9(11-2)6-4-8;/h3-6,10H,7H2,1-2H3;1H

Upstream product

• 702-24-9 4-methoxy-N-methylbenzylamine 
• 1012879-33-2 3-(3-amino-4-fluorophenyl)-7-chloro-1-isopropyl-1,6-naphthyridin-2(1H)-one 

Downstream Products

• 55245-86-8 N‐[(4‐methoxyphenyl)methyl]‐N‐methylcarbamoyl chloride 
• 218900-31-3 N-(tert-butoxycarbonyl)-N-methyl(p-methoxybenzyl)amine 
• 1459695-18-1 C₂₄H₂₁ClF₂N₄O₃S 
• 1459695-33-0 C₂₅H₂₂ClF₂N₃O₄ 

Relevant academic research and scientific papers

DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound. The present invention discloses the unexpected utility of compounds that inhibit cKIT kinase across a broad range of c-KIT mutations, including complex occurrences of primary mutations (KIT exon 9 or 11) and secondary KIT mutations (exons 13, 14, 17 and 18) that may arise in individual, refractory GIST patients. Also unexpected is the utility of compounds of the present invention to inhibit the problematic exon 17 D816V c-KIT mutation, for which there is currently no effective therapy.

Nucleophilic substitution reaction at the nitrogen of arylsulfonamides with phosphide anion

A novel nucleophilic substitution reaction at the nitrogen of arylsulfonamides by means of phosphide anions has been described. This reaction allows for the efficient transformation of arylsulfonamides into synthetically valuable phosphamides, amines, and a variety of protected amines.